Sarcopenia: Causes, Diagnosis, and Evidence-Based Treatment

What Sarcopenia Actually Is

Sarcopenia is the progressive, generalized loss of skeletal muscle mass, strength, and physical performance that comes with aging. The European Working Group on Sarcopenia in Older People (EWGSOP2) updated its consensus definition in 2018 to place low muscle strength as the primary marker, with low muscle quantity or quality confirming the diagnosis, and poor physical performance classifying severity as "severe sarcopenia." [1]

The word comes from the Greek roots for flesh and poverty, and the clinical picture matches that etymology. A 70-year-old with sarcopenia may weigh the same as they did at 50, yet carry 8 to 10 kg less lean tissue and correspondingly more fat. Standard BMI misses this entirely.

Prevalence estimates vary because diagnostic thresholds differ across populations, but meta-analyses consistently place community-dwelling sarcopenia at 10 to 27% in adults over 60 and roughly 50% in adults over 80. [2] The FNIH Sarcopenia Project analyzed data from nine cohorts (combined N more than 26,000) and established grip-strength cutoffs of <26 kg in men and <16 kg in women as the operationally best predictors of mobility limitation. [3] EWGSOP2 uses slightly different cutoffs (<27 kg men, <16 kg women) and recommends the SARC-F questionnaire for initial community screening, with a score of 4 or higher triggering formal assessment.

Why Muscle Wastes With Age

Muscle loss after 50 is not a single-mechanism problem. Anabolic resistance sits at the center: aging muscle requires a higher leucine threshold to trigger muscle protein synthesis than younger tissue does. [4] A 35-year-old may mount a full synthetic response to 20 g of whey protein, while a 70-year-old may need 35 to 40 g of the same protein source to achieve the same effect.

Three other mechanisms compound the problem in parallel.

First, motor neuron dropout reduces the number of fast-twitch (type II) muscle fibers that can be recruited. Type II fibers generate power and are the ones most responsible for fall prevention. Second, chronic low-grade inflammation, sometimes called "inflammaging," elevates interleukin-6 and TNF-alpha, which activate ubiquitin-proteasome pathways that degrade contractile proteins. Third, anabolic hormone decline amplifies both processes: free testosterone falls roughly 1 to 2% per year in men after 30 [5], and IGF-1 drops 14% per decade from midlife onward.

Physical inactivity accelerates all three. Bed rest studies show that healthy young adults lose approximately 0.5% of lower-limb muscle mass per day during immobilization. Older adults lose it faster and recover it more slowly. A 10-day hospitalization in an adult over 65 can wipe out the muscle gains from months of rehabilitation. [6]

How Sarcopenia Differs From Cachexia

Sarcopenia and cachexia both involve skeletal muscle loss, but they are distinct clinical syndromes with different drivers and treatment priorities. Understanding the difference shapes prescribing.

Cachexia is defined by the international consensus definition as a complex metabolic syndrome associated with underlying illness, characterized by muscle loss with or without fat loss that cannot be fully reversed by conventional nutritional support. [7] The Society on Sarcopenia, Cachexia and Wasting Disorders specifies that cachexia requires weight loss greater than 5% in 12 months (or BMI <20), plus three of five criteria: decreased muscle strength, fatigue, anorexia, low fat-free mass index, or abnormal biochemistry (elevated CRP, anemia, low albumin). [7]

The critical difference is systemic inflammation driving obligatory catabolism. Cancer, heart failure, COPD, and chronic kidney disease are the classic precipitants. In these settings, protein supplementation alone is insufficient because pro-inflammatory cytokines continue to activate muscle protein breakdown regardless of substrate availability. Sarcopenia, by contrast, responds meaningfully to resistance exercise and protein optimization even in the absence of disease treatment.

Clinically, a patient can have both. Cancer-related cachexia superimposed on age-related sarcopenia is common and carries worse prognosis than either alone. Ghrelin agonists (anamorelin is approved in Japan for cancer cachexia) and megestrol acetate have been studied in cachectic populations, though evidence for meaningful functional gains remains limited in Western markets. [8]

Sarcopenia and Visceral Fat: The Sarcopenic Obesity Problem

Losing muscle while gaining fat produces a phenotype called sarcopenic obesity. Waist circumference and BMI can appear unremarkable, masking simultaneous muscle deficit and excess visceral adipose tissue.

Visceral fat is metabolically active in ways that subcutaneous fat is not. Adipocytes in the visceral depot secrete higher concentrations of TNF-alpha, IL-6, and free fatty acids directly into the portal circulation. This portal delivery amplifies hepatic insulin resistance and suppresses hepatic IGF-1 production, which then reduces the anabolic signal to muscle. A 2020 analysis in the Journal of Cachexia, Sarcopenia and Muscle found that sarcopenic-obese adults had a 2.5-fold higher risk of cardiovascular mortality compared to adults with neither condition. [9]

Dual-energy X-ray absorptiometry (DXA) is the most practical clinical tool to identify this phenotype in outpatient settings. It quantifies appendicular lean mass index (ALMI: appendicular lean mass in kg divided by height in meters squared), visceral adipose tissue mass, and android-to-gynoid fat ratio in a single low-radiation scan. EWGSOP2 recommends ALMI cutoffs of <7.0 kg/m² in men and <5.5 kg/m² in women to confirm low muscle quantity. [1]

Waist circumference alone misses up to 40% of patients with elevated visceral fat in the sarcopenic-obese phenotype, particularly in Asian and South Asian populations where cardiometabolic risk rises at lower absolute waist measurements. [10]

Diagnosing Sarcopenia Step by Step

The EWGSOP2 algorithm moves through four sequential steps. [1]

Step 1: Screen. Apply SARC-F. Scores of 4 or higher or clinical suspicion (falls, slow gait, weight loss) move the patient forward.

Step 2: Assess strength. Grip strength is the simplest proxy. Handgrip dynamometry takes under 60 seconds. Values below 27 kg (men) or 16 kg (women) indicate probable sarcopenia. Chair-stand time (five chair rises in <12 seconds is normal) is an alternative if a dynamometer is unavailable.

Step 3: Confirm with muscle quantity or quality. DXA is the clinical standard. Computed tomography (CT) at L3 is the research gold standard and is increasingly used in oncology contexts because most staging CTs already include the relevant slice. Bioelectrical impedance analysis (BIA) is acceptable when DXA is unavailable, though its accuracy is affected by hydration.

Step 4: Grade severity. Physical performance tests including the Short Physical Performance Battery (SPPB), usual gait speed (<0.8 m/s is the cutoff for severe sarcopenia), or the Timed Up and Go test classify severity.

Blood biomarkers are not part of routine clinical diagnosis. Serum creatinine-to-cystatin C ratio is an emerging proxy for muscle mass, but it is not yet included in major guidelines. [11]

Resistance Training: The Non-Negotiable Intervention

Resistance exercise is the only intervention with consistent Grade A evidence across multiple systematic reviews and RCTs for improving both muscle mass and function in sarcopenia. The 2021 Cochrane review of progressive resistance training in older adults (45 RCTs, N=2,181) found that progressive resistance training produced significant improvements in muscle strength, gait speed, and physical performance compared to controls. [12]

Protocol specifics matter. The minimum effective dose for older adults appears to be two sessions per week, but three sessions per week produces consistently better results in 12-week trials. Load should progress to 70 to 85% of one-repetition maximum (1RM) for hypertrophic stimulus, which translates to sets of 8 to 12 repetitions taken close to failure. Lighter loads (30 to 50% 1RM) can also produce hypertrophy when sets are taken to near-failure, which is relevant for patients with joint disease or low baseline strength.

Compound movements drive the most functional carryover: squats, leg press, Romanian deadlifts, seated rows, and overhead press. Single-joint isolation work adds volume but should not replace compound lifts in time-limited programming.

For patients who have been sedentary for over a year, three to four weeks of connective-tissue adaptation at moderate loads (50 to 60% 1RM) before progressing to heavier loading reduces injury risk. The SMART program used in the LIFTMOR trial (N=101 postmenopausal women) used supervised high-load progressive resistance training at 85% 1RM and demonstrated a 3.2% improvement in femoral neck bone mineral density and significant lean mass gains over eight months. [13]

Protein: Dose, Distribution, and Source

Protein is the substrate; resistance training is the stimulus. Neither works optimally without the other.

Current evidence, summarized in the PROT-AGE Study Group consensus and the ESPEN guideline on clinical nutrition in older persons, supports 1.2 to 1.6 g of protein per kilogram of body weight per day for older adults with or at risk of sarcopenia. [4] The upper end of that range (up to 2.0 g/kg/day) may be warranted during active rehabilitation or when energy intake is reduced.

Distribution across meals is as important as total daily intake. Single meals delivering 35 to 40 g of high-quality protein appear to maximally stimulate muscle protein synthesis in older adults, compared to 20 to 25 g in younger adults. Spreading protein across three to four meals rather than concentrating it in one or two is supported by acute isotope tracer studies showing better 24-hour net protein balance with even distribution. [14]

Leucine content drives the anabolic response. Whey protein contains roughly 10 to 11% leucine by weight and is digested rapidly, producing a higher and faster leucine peak than casein or soy. For plant-based eaters, a combination of pea and rice protein provides a more complete amino acid profile than either alone, though the leucine content remains somewhat lower than whey. Leucine supplementation (3 to 4 g per serving) added to lower-leucine protein sources can close this gap.

Timing relative to training is less important than total daily intake, but consuming 35 to 40 g of protein within two hours post-exercise takes advantage of the post-exercise anabolic window, particularly in older adults with lower baseline synthetic rates.

Recomp Plateaus and Bulking Plateaus in the Context of Sarcopenia

A recomp plateau (simultaneous fat loss and muscle gain stalling out) and a bulking plateau (muscle gain stopping despite caloric surplus) both share a common root cause worth examining in older or metabolically compromised patients: anabolic resistance.

If a patient over 50 reports four or more weeks of stalled strength despite consistent training, adequate calories, and protein at or above 1.6 g/kg/day, the differential widens beyond program design. Subclinical sarcopenia is on that list. So is low testosterone. NHANES data show that men with total testosterone below 300 ng/dL have roughly 2 kg less lean mass than age-matched eugonadal men, independent of training status. [5]

A practical clinical decision framework for a recomp or bulking plateau in adults over 45:

1. Confirm protein intake with a 3-day food log (target: 1.6 g/kg/day minimum).
2. Check training load progression. Strength should increase at least 5% over 4 to 6 weeks.
3. Order fasting total and free testosterone, IGF-1, and TSH. Hypothyroidism blunts both muscle protein synthesis and fat oxidation.
4. Obtain DXA to establish ALMI baseline and quantify visceral fat.
5. If ALMI is below cutoff and testosterone is below 300 ng/dL (men) or free testosterone is below the lower quartile for age in women, discuss pharmacologic adjuncts.
6. Reassess at 12 weeks with same-conditions DXA.

This framework reduces the error of adjusting diet or programming when the real limiting factor is hormonal or diagnostic.

GLP-1 Medications and Lean Mass Preservation

GLP-1 receptor agonists are now widely prescribed, and sarcopenia risk during GLP-1-induced weight loss is a real clinical concern. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean total body weight loss at 68 weeks versus 2.4% in the placebo group (P<0.001). [15] DXA substudies from STEP-1 showed that approximately 39% of the weight lost was fat-free mass, compared to roughly 25% fat-free mass loss seen in supervised caloric restriction with resistance training.

This means that on semaglutide without a co-prescribed resistance training program, a 100 kg patient who loses 15 kg may lose approximately 5.85 kg of lean tissue. Over years of use, that trajectory worsens baseline sarcopenia in older adults or creates sarcopenic obesity in patients who were lean at baseline.

The 2023 American College of Sports Medicine position statement on exercise and GLP-1 pharmacotherapy explicitly recommends concurrent resistance training for all patients on GLP-1 agents, with protein targets at the higher end of guidelines (1.6 to 2.0 g/kg/day) to mitigate lean mass losses. [16]

Tirzepatide data from SURMOUNT-1 (N=2,539) showed 22.5% mean weight loss at 72 weeks in the 15 mg arm versus 2.4% placebo. [17] DXA substudy data from SURMOUNT-1 suggested a similar or slightly better lean mass preservation ratio than semaglutide, but without concurrent exercise the absolute lean mass losses at higher weight-loss magnitudes were still clinically meaningful.

For patients on GLP-1 agents who are at risk for sarcopenia (over 60, low ALMI, or prior sarcopenia diagnosis), the clinical recommendation is to co-prescribe structured resistance training from day one of GLP-1 initiation rather than adding it after weight loss has occurred.

Pharmacologic Adjuncts Beyond Lifestyle

Lifestyle intervention is primary. Several pharmacologic options are used adjunctively in specific clinical scenarios.

Testosterone replacement therapy (TRT). In men with confirmed hypogonadism (two morning total testosterone measurements below 300 ng/dL per Endocrine Society guidelines), TRT produces meaningful lean mass gains. The Testosterone Trials (TTrials, N=790 men over 65 with testosterone below 275 ng/dL) found that 12 months of testosterone gel increased lean mass by approximately 1.6 kg compared to placebo. [18] The Endocrine Society 2018 guideline states: "We suggest testosterone therapy for men with age-related decline in testosterone who have symptoms and signs of androgen deficiency." [19]

Creatine monohydrate. The evidence base for creatine in sarcopenia is more consistent than its gym-culture reputation suggests. A 2017 meta-analysis of 22 RCTs found that creatine supplementation plus resistance training increased lean mass by 1.37 kg more than resistance training alone in older adults (mean age 64). [20] The standard dose is 3 to 5 g per day; loading phases are unnecessary for long-term use.

Vitamin D. Muscle fibers express the vitamin D receptor. Deficiency (<20 ng/mL) is associated with reduced type II fiber cross-sectional area and increased fall risk. Supplementation to serum 25(OH)D levels above 30 ng/mL is recommended by the Endocrine Society, with 1,500 to 2 to 000 IU daily typically required for deficient adults. [21] Correcting deficiency alone does not produce large muscle gains but removes a correctable suppressor of training response.

Selective androgen receptor modulators (SARMs). Agents like enobosarm (ostarine) showed lean mass gains in phase II cancer cachexia trials but have not achieved FDA approval for sarcopenia, and their long-term cardiovascular and hepatic safety profiles remain under investigation. They are not recommended outside of clinical trials.

Monitoring Response to Treatment

Reassessment timing and metrics determine whether an intervention is working or should be adjusted.

For resistance training programs, strength gains (not body weight) are the primary short-term metric. Expect measurable grip strength or lower-body strength improvements within 6 to 8 weeks in most adults over 60, preceding visible changes in lean mass. Gait speed improvement typically follows strength gains by 4 to 6 weeks.

For DXA-based monitoring, a minimum of 12 weeks between scans is needed to detect meaningful changes above the measurement error of the device (approximately 0.3 kg for lean mass on most clinical DXA systems). A 24-week scan interval is more informative and more practical for most outpatient settings.

The EWGSOP2 consensus recommends re-assessing the full diagnostic algorithm (strength, quantity, performance) every 6 months in patients with confirmed sarcopenia on active treatment, and annually in patients with probable sarcopenia on preventive intervention. [1]

The Physical Performance Battery (SPPB), which scores balance, gait speed, and chair-stand time on a 0 to 12 scale, is sensitive enough to detect treatment response and carries strong prognostic weight: each 1-point increase in SPPB score is associated with a 10% reduction in mortality risk in older community-dwelling adults. [22]